Radioactive and normal stent insertion for the treatment of malignant airway stenosis: A meta-analysis.

PURPOSE

To demonstrate the advantage of radioactive stent (RS) for treating malignant airway stenosis (MAS) in reducing the stent restenosis rate and increasing overall survival (OS).

MATERIALS AND METHODS

Relevant studies in Pubmed, Embase, and Cochrane Library databases were identified. The rate of stent restenosis was the primary endpoint, whereas secondary endpoints were rates of stent-related complications, OS, and complete relief of dyspnea. This meta-analysis was conducted using RevMan v5.3.

RESULTS

Five total studies including 131 and 119 patients that underwent RS and normal stent (NS) insertion, respectively, were identified and included in this meta-analysis. Four studies were randomized controlled trials and one study was retrospective study. Pooled rates of complete relief of dyspnea, chest pain, hemoptysis, and fistula formation were similar between these two groups (p = 0.72, 0.77, 0.92, and 0.62, respectively). Pooled Δstenosis grade was comparable between these two groups (p = 0.72). RS insertion was linked to a significant lower pooled stent restenosis rate, increased OS, and higher 3-month survival rate relative to NS insertion (p< 0.00001, 0.0001, and 0.03, respectively). Pooled 6-months survival rates was higher in RS group without significant difference (p = 0.06). Pooled stent restenosis rate was significant higher in RS group based on each subgroup analysis. No evidence of publication bias for these endpoints was detected via funnel plot.

CONCLUSIONS

This meta-analysis revealed that RS insertion was sufficient to reduce rates of stent restenosis and to prolong patient OS relative to NS insertion when used to treat MAS.